Larimar Therapeutics, Inc. LRMR
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Larimar Therapeutics, Inc. (LRMR) is a healthcare company listed in the US with a market value of about $314M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -82%.
About Larimar Therapeutics
Larimar Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. It was profitable in 0 of the last 10 years in our data. Its share count rose by 303% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Net income | -$166M | -$81M | -$37M | -$35M | -$51M | -$42M | -$23M | -$61M | -$52M | -$58M |
| Free cash flow | -$113M | -$71M | -$34M | -$28M | -$42M | -$42M | -$23M | -$52M | -$44M | -$53M |
| EPS (diluted) | $-1.59 | $-1.32 | $-0.84 | $-1.37 | $-2.95 | $-3.57 | $-3.80 | $-11.65 | $-11.65 | $-13.00 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -210.0% | -51.4% | -47.9% | -31.4% | -71.7% | -44.5% | -106.1% | -259.5% | -54.0% | -46.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $14.40, 377% above the current price; targets range from $5.00 to $26.00; the consensus rating is “Strong buy”; expected EPS is $-1.37 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Larimar Therapeutics pay a dividend?
Not currently.
Is Larimar Therapeutics a good stock to buy?
We do not give buy or sell advice. Larimar Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.